Biologics and biosimilars in Brazil – the strategic questions

By Priscila Mayumi Kashiwabara

May 29, 2020

Biologics and biosimilars in Brazil – the strategic questions

Our partners Anderson Ribeiro, Aline Ferreira and Priscila Kashiwabara and patent specialist Marisa Momoli authored the chapter "Biologics and biosimilars in Brazil – the strategic questions". This article first appeared in IAM Life Sciences: Key issues for senior life sciences executives 2020, a supplement to IAM, published by Law Business Research – IP Division.

Click below to access the full chapter.

See file

Back

Last by Priscila Mayumi Kashiwabara

December 29, 2021

Sequence listing in ST.26 format is officially postponed until July 1, 2022 by the Brazilian PTO

On December 28, 2021, the BRPTO published, by means of the Official Gazette nº 2660, the Ordinance #56/2021, which establishes the procedures … Sequence listing in ST.26 format is officially postponed until July 1, 2022 by the Brazilian PTO

July 5, 2021

Personalised medicine in Brazil: IP and regulatory challenges

Our partners Anderson Ribeiro, Aline Ferreira and Priscila Kashiwabara authored the chapter "Personalised medicine in Brazil: IP and regulatory challenges". This article first … Personalised medicine in Brazil: IP and regulatory challenges

March 30, 2021

Brazilian PTO extends the Patent Backlog Fighting Project

Continuing with the goal of reducing the number of patent applications pending decision, the Brazilian PTO (“BPTO”) published the Ordinance/INPI/PR N° 21, … Brazilian PTO extends the Patent Backlog Fighting Project